Interleukin-1 alpha (IL-1α) is a pro-inflammatory cytokine of the IL-1 family that plays a central role in inflammation and immune responses. In the central nervous system, IL-1α is produced by astrocytes, microglia, neurons, and endothelial cells, contributing to neuroinflammation in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions [1].
| Interleukin-1 Alpha (IL-1α) |
|---|
| Protein Name | Interleukin-1 alpha |
| Gene Symbol | IL1A |
| UniProt ID | P01546 |
| Molecular Weight | 17 kDa (pro-IL-1α), 12 kDa (mature) |
| Subcellular Localization | Cytoplasm, Secreted |
| Protein Family | IL-1 family |
| Brain Expression | Astrocytes, Microglia, Neurons, Endothelial cells |
Interleukin-1 alpha (IL-1α) is a pro-inflammatory cytokine that plays a central role in inflammation. Unlike IL-1β, IL-1α is constitutively expressed in many tissues including the brain and is released upon cell damage as an alarmin (endogenous danger signal). It binds to the IL-1R1 receptor to initiate inflammatory signaling cascades [2].
- Pro-IL-1α: Full-length precursor (271 amino acids, 31 kDa)
- Mature IL-1α: Processed form (17 kDa, 159 amino acids)
- β-trefoil fold: Characteristic of IL-1 family proteins
- N-terminal prodomain: Functions as a carrier/precursor
- C-terminal mature domain: Receptor-binding region
- Nuclear localization signals: Present in prodomain
- Receptor: IL-1R1 (type I IL-1 receptor)
- Co-receptor: IL-1RAcP (IL-1 receptor accessory protein)
- Signaling pathways:
- MyD88-dependent NF-κB activation
- MAPK pathways (ERK, p38, JNK)
- AP-1 transcription factor activation
IL-1α functions as an alarmin when released from damaged cells:
- Constitutively expressed in epithelial, endothelial, glial cells
- Released passively upon cell necrosis or pyroptosis
- Active secretion via unconventional pathway
- Functions: Initiates sterile inflammation, tissue repair
| Feature |
IL-1α |
IL-1β |
| Expression |
Constitutive |
Inducible |
| Activity |
Cell-associated |
Secreted |
| Processing |
Calpain cleavage |
Caspase-1 cleavage |
| Function |
Alarmin |
Classical cytokine |
- Regulates neural progenitor cell proliferation
- Modulates synaptic plasticity and memory formation
- Involved in seizure threshold regulation
Following CNS injury:
- Rapid release from damaged neurons
- Initiates inflammatory cascade
- Promotes glial scar formation
- Coordinates tissue repair
Evidence:
- Elevated in AD brain, especially around amyloid plaques [3]
- Increased IL-1α in CSF of AD patients
- Genetic variants associated with AD risk
Mechanisms:
- Amyloid processing: Promotes APP processing via BACE1
- Microglial activation: Drives chronic neuroinflammation
- Synaptic dysfunction: Impairs LTP and synaptic plasticity
- Tau pathology: May promote tau phosphorylation
- Blood-brain barrier: Disrupts BBB integrity
Evidence:
- Elevated in substantia nigra of PD patients
- Correlates with disease severity
- Found in Lewy bodies
Mechanisms:
- Dopaminergic neuron toxicity: Direct toxic effects
- Microglial activation: Promotes M1 phenotype
- α-synuclein aggregation: May accelerate aggregation
- Neuroinflammation: Sustains chronic inflammation
- Elevated in spinal cord of ALS patients
- Contributes to motor neuron death
- Therapeutic targeting shows promise
- Promotes demyelination
- Enhances leukocyte infiltration
- IL-1R1 blockade is protective in animal models
- Released immediately after injury
- Predicts outcomes
- IL-1R1 antagonists neuroprotective
- CSF IL-1α: Marker of neuroinflammation
- Serum IL-1α: Associated with disease progression
| Approach |
Agent |
Status |
| IL-1R1 blockade |
Anakinra |
Clinical trials |
| IL-1R1 blockade |
Canakinumab |
Clinical trials |
| IL-1R1 blockade |
Rilonacept |
Research |
| IL-1α neutralization |
MAB-cIL-1α |
Preclinical |
- Anakinra: IL-1R1 antagonist, in trials for AD
- Canakinumab: Anti-IL-1β antibody, cardiovascular trials
- Minocycline: Inhibits IL-1α production
- IL1A polymorphisms associated with AD risk
- Promoter variants affect expression levels
- Combination with other cytokines (IL-6, TNF-α)
- Predictive value for treatment response
The study of Il 1Α Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Shaftel SS, et al. IL-1 in the brain. J Neuroinflammation. 2023
[2] Sims JE, et al. IL-1 and IL-1 receptors. Immunol Rev. 2022
[3] Griffin WS, et al. IL-1 and Alzheimer's disease. Neurobiol Aging. 2020